Marc Darrow, MD, JD
Patients interested in regenerative medicine often ask whether exosomes can help an arthritic joint heal. The scientific interest is understandable: cells communicate through biological signals, and researchers are investigating whether selected signals can influence inflammation and tissue repair.
My starting point is to separate three questions. What happens in a laboratory? What has been observed in patients? And does a controlled trial show that the treatment works better than the comparison? Those questions can produce different answers.
For osteoarthritis, exosomes remain an investigational approach. There are encouraging early human observations, but a placebo-controlled trial did not show an added benefit. Neither result should be omitted when explaining the field.
Osteoarthritis involves the whole joint
Osteoarthritis is more than gradual cartilage wear. Cartilage cells, the surrounding matrix, the joint lining, immune activity, and bone beneath the cartilage interact. Changes in one part of that system can affect the others. This helps explain interest in treatments aimed at the joint environment rather than cartilage thickness alone. (1)
However, pain is still a clinical problem requiring a diagnosis. An arthritic X-ray does not independently determine whether pain is coming from the joint, an adjacent tendon, an unstable supporting structure, or several contributors.
What are exosomes and extracellular vesicles?
Extracellular vesicles are membrane-enclosed particles released by cells. They can carry proteins, lipids, and regulatory genetic material that influence other cells. Exosomes are a particular type of vesicle; the terms should not automatically be treated as interchangeable. These particles are not living stem cells. (2)
Their source matters. Signals from inflamed or damaged tissues may participate in disease, while selected vesicles from other sources are being studied for protective effects. A larger particle count does not, by itself, establish a stronger repair effect. Product identity and biological activity matter more than an impressive number on a label. (2)
Why researchers are interested in cell-derived signaling
Experimental research suggests that selected MSC-derived vesicles may influence inflammatory responses, cartilage-cell survival, and the balance between matrix production and breakdown. This is part of the wider interest in paracrine signaling: cells affecting nearby cells through released signals, rather than simply turning into replacement tissue. These mechanisms offer reasons for research, not proof of reliable cartilage regeneration in a person. (1)
Laboratory and animal models also help investigate immune effects, stress responses, and possible biomarkers. Results from a controlled experimental injury in an animal cannot predict the response of every human arthritic joint. Dose, delivery, processing, and disease stage can all differ. (2)
2025 cord-derived exosome study: an early human signal
Wang and colleagues reported a study involving 41 patients and 45 knees with grade 2 or 3 osteoarthritis. Participants received umbilical cord MSC-derived exosomes in three active-dose groups, with three injections and follow-up extending to nine months. Some symptom measures and exploratory MRI findings improved, without major reported safety signals. (3)
Although described as randomized and double-blind, this was a comparison between active doses, without saline or sham controls. Improvement from baseline therefore does not establish benefit over placebo or prove cartilage regeneration. The sample was too small to establish broad safety. The injected material was a vesicle preparation produced from cultured source cells, rather than live culture-expanded cells or ordinary donated cord tissue.
2024 placebo-controlled vesicle trial: no additional benefit
Bolandnazar and colleagues enrolled 31 people with bilateral grade 2 or 3 knee osteoarthritis. Each person’s knees were randomized to a single placental MSC-derived extracellular-vesicle injection or saline. Twenty-nine patients completed analysis. At two and six months, symptoms did not differ significantly between groups; MRI findings also showed no significant between-group difference at six months. No systemic complications or severe local reactions were reported. (4)
The negative result applies to this product and regimen. It does not settle every vesicle formulation, but it shows why a placebo comparison matters.
How should these studies be compared?
| Feature | 2025 cord-derived study (3) | 2024 placental-vesicle trial (4) |
|---|---|---|
| Comparison | Three active doses | Vesicles versus saline |
| Regimen | Three injections | Single injection |
| Main signal | Some improvement from baseline | No superiority over saline |
| Central limitation | No placebo group | Small trial of one product/regimen |
These are not a head-to-head test of cord versus placental products, or repeated versus single injections. Their different designs prevent that conclusion. A future direct comparison would need to control those differences.
A 2026 review of biological rationale and clinical evidence reached a measured conclusion: extracellular vesicles are promising, but efficacy findings remain limited and inconsistent, and routine clinical use is not supported by the current evidence. The authors emphasized standardized manufacturing, validated potency testing, and stronger randomized trials. This review synthesizes existing evidence; it is not another independent successful treatment trial. (5)
Does an MRI change prove cartilage regrowth?
A structural claim requires more than a patient feeling better or an image appearing different. Investigators need consistent acquisition and measurement methods, appropriate controls, and evidence that any change is meaningful and durable. A positive symptom result and a positive structural result are separate outcomes.
Likewise, reporting no serious complications in a small study is reassuring within that observation period. It cannot exclude uncommon events or establish the safety of other products, injection schedules, or manufacturing methods.
Are exosomes the same as Wharton’s jelly, PRP, or marrow concentrate?
No. PRP concentrates platelets from a patient’s blood. Bone marrow concentrate is a mixed preparation from the patient’s marrow. Wharton’s jelly is donated umbilical cord connective tissue. A characterized exosome or vesicle preparation is a different product.
Evidence from one source cannot be transferred simply because another preparation is also called regenerative. A study of isolated vesicles does not establish the effectiveness of a cord-tissue allograft, and a PRP response does not establish that adding exosomes improves the result. Our comparison of PRP, bone marrow, and Wharton’s jelly for knee pain explains those preparation differences.
What remains uncertain?
The important unanswered questions include which product, patient population, dose, and schedule could provide a meaningful benefit. Researchers also need to establish reproducible composition, storage stability, biological potency, and longer-term safety. A product used in practice would need to match the product tested in research. (5)
Even a future effective symptom treatment would not automatically correct major malalignment, a loose fragment, or recurrent joint dislocation. Those problems require their own assessment. Evidence from these knee studies also should not be presented as established treatment evidence for hip, shoulder, hand, or spinal osteoarthritis.
What is the FDA status?
The FDA states that there are no FDA-approved exosome products and that the regenerative products addressed in its consumer alert have not been approved for orthopedic conditions such as osteoarthritis. Publication of a study, registration of a company, or the label “cell-free” does not establish approval. (6)
The studies discussed here describe investigational research, not an established exosome service offered by our clinic. The research field deserves careful investigation without promises of cartilage restoration or guaranteed surgery avoidance.
Summary
The diagnosis comes before the product. I want to know what hurts, how it limits the patient, and whether the proposed intervention has evidence relevant to that problem. An explanation of how cells communicate can be useful, but it should lead to a clinical question that can be tested.
Exosomes may eventually help researchers develop more targeted approaches to osteoarthritis. At present, the useful message is that human research has begun.
For related context, see our knee osteoarthritis article and our guide to PRP, cell-based preparations, and exosomes.
References
1 Wang X, Xu L, Wu Z, et al. Exosomes of stem cells: a potential frontier in the treatment of osteoarthritis. Precis Clin Med. 2025;8(1):pbae032. Published online November 26, 2024. doi:10.1093/pcmedi/pbae032.
2 Sun C, Teng F, Xia Y. Extracellular vesicles in osteoarthritis: mechanisms, therapeutic potential, and diagnostic applications. Front Immunol. 2025;16:1595095. doi:10.3389/fimmu.2025.1595095.
3 Wang Y, Kong Y, Du J, et al. Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis: from preclinical to clinical research. J Transl Med. 2025;23:641. doi:10.1186/s12967-025-06623-y.
4 Bolandnazar NS, Raeissadat SA, Haghighatkhah H, et al. Safety and efficacy of placental mesenchymal stromal cells-derived extracellular vesicles in knee osteoarthritis: a randomized, triple-blind, placebo-controlled clinical trial. BMC Musculoskelet Disord. 2024;25:856. doi:10.1186/s12891-024-07979-w.
5 Al-Jeabory M, Pecold J, Maslyk M, et al. Exosomes and Small Extracellular Vesicles as an Alternative to Mesenchymal Stromal Cell Therapy in Knee Osteoarthritis: From Biological Rationale to Clinical Evidence. Int J Mol Sci. 2026;27(9):3737. doi:10.3390/ijms27093737.
6 U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. July 22, 2020. Accessed November 14, 2026.
Marc Darrow, M.D., J.D., is one of the world’s most experienced Regenerative Medicine doctors. He has more than 30 Years of expertise in regenerative medicine techniques and has treated thousands of patients. He uses non-surgical therapy to reduce pain in joints, tendons, ligaments, and a variety of other ailments and disorders throughout the body, including back and neck discomfort. He taught at UCLA and received Board Certification in Physical Medicine and Rehabilitation.
